Compare NTST & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | ANAB |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2020 | 2015 |
| Metric | NTST | ANAB |
|---|---|---|
| Price | $20.41 | $55.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $22.02 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 955.6K | 356.0K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 150.00 | 91.02 |
| EPS | ★ 0.12 | N/A |
| Revenue | $195,006,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $16.25 | $52.14 |
| P/E Ratio | $170.33 | ★ N/A |
| Revenue Growth | 19.79 | ★ 157.01 |
| 52 Week Low | $17.02 | $17.11 |
| 52 Week High | $22.47 | $73.30 |
| Indicator | NTST | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 45.73 |
| Support Level | $20.25 | $53.46 |
| Resistance Level | $20.82 | $57.70 |
| Average True Range (ATR) | 0.31 | 2.43 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 31.65 | 18.14 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).